Suspended
Status | Suspended |
Decision | Selected |
Process | STA 2018 |
ID number | 1467 |
Project Team
Project lead | Michelle Adhemar |
Email enquiries
- If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
Date | Update |
---|---|
28 September 2018 | Suspended. Suspended |
28 August 2018 - 25 September 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
18 September 2018 | The National Institute for Health and Care Excellence (NICE) has been asked to conduct an appraisal of elotuzumab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma ID1467. We have recently invited stakeholders to respond to a written consultation on the draft scope. The company that is developing elotuzumab have shared confidential information with NICE. In light of this information the Institute will not be progressing with the scoping exercise. Consequently the consultation on the draft scope will be closed early. The topic will still progress to Technology Appraisal stage If you have any comments or concerns please contact the project manager for this appraisal Michelle Adhemar at michelle.adhemar@nice.org.uk |
13 February 2018 | Referral |
13 February 2018 | In progress. Topic referred |
For further information on our processes and methods, please see our CHTE processes and methods manual